newsfilter
← Latest News
GlobeNewswire·

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Designation granted for BDTX-1535 as second-line treatment for EGFR mutant/C797S NSCLC